A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Completed
Indivior Inc.
Phase 2
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil
sustained release tablets taken every 12 hours compared to placebo in subjects with acute
back spasms in the lumbar region.
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Completed
XenoPort, Inc.
Phase 2
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil
sustained release tablets taken every 12 hours compared to placebo in subjects with acute
back spasms in the lumbar region.
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Completed
Indivior Inc.
Phase 2
The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986)
versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite
therapy with approved doses of a Proton Pump Inhibitor (PPI).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
